THAP9

Across TCGA pan-cancer cohorts, THAP9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated THAP9 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher THAP9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated THAP9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where THAP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.712	1.000	.020	5	view →
LUAD	OS	Tertile	III,IV	0.408	0.753	.040	3	view →
PDAC	OS	Median	III,IV	0.984	0.508	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

THAP9–LSCC (DFS)

Open the LSCC breakdown →